A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL

Craig S. Sauter, Matthew J. Matasar, Heiko Schoder, Sean M. Devlin, Pamela Drullinsky, John Gerecitano, Anita Kumar, Ariela Noy, Maria L. Palomba, Carol S. Portlock, David J. Straus, Andrew D. Zelenetz, Susan J. McCall, Shoshana T. Miller, Amanda I. Courtien, Anas Younes, Craig Moskowitz

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In the postrituximab era, approximately half of the patients with relapsed or refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) fail to achieve a chemosensitive response to standard salvage therapy, and are thus ineligible to proceed to autologous stem cell transplantation with curative intent. The Bruton tyrosine kinase inhibitor ibrutinib demonstrates single-agent activity in rel/ref DLBCL, particularly of non–germinal center (non-GC) cell of origin. We conducted a single-center phase 1 study evaluating dose-escalated ibrutinib, in a 3-by-3 design, in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in physiologically transplant-eligible rel/ref DLBCL patients. Twenty-one patients have been treated and are evaluable for toxicity with no dose-limiting toxicities observed through expansion with ibrutinib at 840 mg daily at dose level 3. Of the 20 patients evaluable for response, per modern International Conference on Malignant Lymphoma criteria, 11 patients achieved complete remission (CR) and 7 patients achieved partial remission for an overall response rate of 90%. All evaluable patients with non-GC DLBCL achieved a metabolic CR. Ibrutinib in combination with R-ICE demonstrates tolerability and efficacy in rel/ref DLBCL, particularly of non-GC phenotype. This treatment program warrants further investigation in later-phase studies.

Original languageEnglish (US)
Pages (from-to)1805-1808
Number of pages4
JournalBlood
Volume131
Issue number16
DOIs
StatePublished - Apr 19 2018
Externally publishedYes

Fingerprint

Ifosfamide
Lymphoma, Large B-Cell, Diffuse
Carboplatin
Etoposide
Refractory materials
Toxicity
Salvaging
Transplants
Stem cells
Cells
Salvage Therapy
Stem Cell Transplantation
PCI 32765
Rituximab
Phenotype

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Sauter, C. S., Matasar, M. J., Schoder, H., Devlin, S. M., Drullinsky, P., Gerecitano, J., ... Moskowitz, C. (2018). A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood, 131(16), 1805-1808. https://doi.org/10.1182/blood-2017-08-802561

A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. / Sauter, Craig S.; Matasar, Matthew J.; Schoder, Heiko; Devlin, Sean M.; Drullinsky, Pamela; Gerecitano, John; Kumar, Anita; Noy, Ariela; Palomba, Maria L.; Portlock, Carol S.; Straus, David J.; Zelenetz, Andrew D.; McCall, Susan J.; Miller, Shoshana T.; Courtien, Amanda I.; Younes, Anas; Moskowitz, Craig.

In: Blood, Vol. 131, No. 16, 19.04.2018, p. 1805-1808.

Research output: Contribution to journalArticle

Sauter, CS, Matasar, MJ, Schoder, H, Devlin, SM, Drullinsky, P, Gerecitano, J, Kumar, A, Noy, A, Palomba, ML, Portlock, CS, Straus, DJ, Zelenetz, AD, McCall, SJ, Miller, ST, Courtien, AI, Younes, A & Moskowitz, C 2018, 'A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL', Blood, vol. 131, no. 16, pp. 1805-1808. https://doi.org/10.1182/blood-2017-08-802561
Sauter CS, Matasar MJ, Schoder H, Devlin SM, Drullinsky P, Gerecitano J et al. A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood. 2018 Apr 19;131(16):1805-1808. https://doi.org/10.1182/blood-2017-08-802561
Sauter, Craig S. ; Matasar, Matthew J. ; Schoder, Heiko ; Devlin, Sean M. ; Drullinsky, Pamela ; Gerecitano, John ; Kumar, Anita ; Noy, Ariela ; Palomba, Maria L. ; Portlock, Carol S. ; Straus, David J. ; Zelenetz, Andrew D. ; McCall, Susan J. ; Miller, Shoshana T. ; Courtien, Amanda I. ; Younes, Anas ; Moskowitz, Craig. / A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. In: Blood. 2018 ; Vol. 131, No. 16. pp. 1805-1808.
@article{9e24188e542d4e43ac9373bd717cb3eb,
title = "A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL",
abstract = "In the postrituximab era, approximately half of the patients with relapsed or refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) fail to achieve a chemosensitive response to standard salvage therapy, and are thus ineligible to proceed to autologous stem cell transplantation with curative intent. The Bruton tyrosine kinase inhibitor ibrutinib demonstrates single-agent activity in rel/ref DLBCL, particularly of non–germinal center (non-GC) cell of origin. We conducted a single-center phase 1 study evaluating dose-escalated ibrutinib, in a 3-by-3 design, in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in physiologically transplant-eligible rel/ref DLBCL patients. Twenty-one patients have been treated and are evaluable for toxicity with no dose-limiting toxicities observed through expansion with ibrutinib at 840 mg daily at dose level 3. Of the 20 patients evaluable for response, per modern International Conference on Malignant Lymphoma criteria, 11 patients achieved complete remission (CR) and 7 patients achieved partial remission for an overall response rate of 90{\%}. All evaluable patients with non-GC DLBCL achieved a metabolic CR. Ibrutinib in combination with R-ICE demonstrates tolerability and efficacy in rel/ref DLBCL, particularly of non-GC phenotype. This treatment program warrants further investigation in later-phase studies.",
author = "Sauter, {Craig S.} and Matasar, {Matthew J.} and Heiko Schoder and Devlin, {Sean M.} and Pamela Drullinsky and John Gerecitano and Anita Kumar and Ariela Noy and Palomba, {Maria L.} and Portlock, {Carol S.} and Straus, {David J.} and Zelenetz, {Andrew D.} and McCall, {Susan J.} and Miller, {Shoshana T.} and Courtien, {Amanda I.} and Anas Younes and Craig Moskowitz",
year = "2018",
month = "4",
day = "19",
doi = "10.1182/blood-2017-08-802561",
language = "English (US)",
volume = "131",
pages = "1805--1808",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "16",

}

TY - JOUR

T1 - A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL

AU - Sauter, Craig S.

AU - Matasar, Matthew J.

AU - Schoder, Heiko

AU - Devlin, Sean M.

AU - Drullinsky, Pamela

AU - Gerecitano, John

AU - Kumar, Anita

AU - Noy, Ariela

AU - Palomba, Maria L.

AU - Portlock, Carol S.

AU - Straus, David J.

AU - Zelenetz, Andrew D.

AU - McCall, Susan J.

AU - Miller, Shoshana T.

AU - Courtien, Amanda I.

AU - Younes, Anas

AU - Moskowitz, Craig

PY - 2018/4/19

Y1 - 2018/4/19

N2 - In the postrituximab era, approximately half of the patients with relapsed or refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) fail to achieve a chemosensitive response to standard salvage therapy, and are thus ineligible to proceed to autologous stem cell transplantation with curative intent. The Bruton tyrosine kinase inhibitor ibrutinib demonstrates single-agent activity in rel/ref DLBCL, particularly of non–germinal center (non-GC) cell of origin. We conducted a single-center phase 1 study evaluating dose-escalated ibrutinib, in a 3-by-3 design, in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in physiologically transplant-eligible rel/ref DLBCL patients. Twenty-one patients have been treated and are evaluable for toxicity with no dose-limiting toxicities observed through expansion with ibrutinib at 840 mg daily at dose level 3. Of the 20 patients evaluable for response, per modern International Conference on Malignant Lymphoma criteria, 11 patients achieved complete remission (CR) and 7 patients achieved partial remission for an overall response rate of 90%. All evaluable patients with non-GC DLBCL achieved a metabolic CR. Ibrutinib in combination with R-ICE demonstrates tolerability and efficacy in rel/ref DLBCL, particularly of non-GC phenotype. This treatment program warrants further investigation in later-phase studies.

AB - In the postrituximab era, approximately half of the patients with relapsed or refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) fail to achieve a chemosensitive response to standard salvage therapy, and are thus ineligible to proceed to autologous stem cell transplantation with curative intent. The Bruton tyrosine kinase inhibitor ibrutinib demonstrates single-agent activity in rel/ref DLBCL, particularly of non–germinal center (non-GC) cell of origin. We conducted a single-center phase 1 study evaluating dose-escalated ibrutinib, in a 3-by-3 design, in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in physiologically transplant-eligible rel/ref DLBCL patients. Twenty-one patients have been treated and are evaluable for toxicity with no dose-limiting toxicities observed through expansion with ibrutinib at 840 mg daily at dose level 3. Of the 20 patients evaluable for response, per modern International Conference on Malignant Lymphoma criteria, 11 patients achieved complete remission (CR) and 7 patients achieved partial remission for an overall response rate of 90%. All evaluable patients with non-GC DLBCL achieved a metabolic CR. Ibrutinib in combination with R-ICE demonstrates tolerability and efficacy in rel/ref DLBCL, particularly of non-GC phenotype. This treatment program warrants further investigation in later-phase studies.

UR - http://www.scopus.com/inward/record.url?scp=85047603395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047603395&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-08-802561

DO - 10.1182/blood-2017-08-802561

M3 - Article

C2 - 29386196

AN - SCOPUS:85047603395

VL - 131

SP - 1805

EP - 1808

JO - Blood

JF - Blood

SN - 0006-4971

IS - 16

ER -